3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Lymphoma
74
Lymphoma, Large B-Cell, Diffuse
55
Lymphoma, Non-Hodgkin
54
Glioblastoma
41
Lymphoma, Mantle-Cell
40
Lymphoma, Follicular
37
Hodgkin Disease
36
Central Nervous System Neoplasms
32
Gliosarcoma
29
Brain Neoplasms
28
Astrocytoma
28
Lymphoma, Large-Cell, Immunoblastic
26
Burkitt Lymphoma
25
Multiple Myeloma
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Glioma
20
Oligodendroglioma
16
Lymphoma, B-Cell, Marginal Zone
15
Neoplasms, Plasma Cell
14
Leukemia
13
Recurrence
10
Lymphoma, B-Cell
9
Lymphoma, T-Cell
8
Waldenstrom Macroglobulinemia
6
Lymphoma, T-Cell, Cutaneous
6
Leukemia, Myeloid, Acute
6
Ependymoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, Large-Cell, Anaplastic
5
Interventions
Gemcitabine
679
130-nm albumin-bound paclitaxel
198
Fluorouracil
186
Oxaliplatin
175
Albumin-Bound Paclitaxel
151
Capecitabine
137
Leucovorin
131
Irinotecan
113
Radiotherapy
95
Taxes
83
pembrolizumab
80
Cisplatin
72
Erlotinib Hydrochloride
69
Radiosurgery
67
Nivolumab
56
Bevacizumab
54
Drug Therapy
52
Cyclophosphamide
49
Magnetic Resonance Spectroscopy
46
folfirinox
42
Docetaxel
41
Cetuximab
40
Specimen Handling
37
irinotecan sucrosofate
36
S 1 (combination)
36
Biopsy
31
Radiation
29
Paclitaxel
29
Ipilimumab
27
durvalumab
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Neoplasms
×
Carmustine
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled